Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet concentrates re-suspended in autologous plasma are a blood component used for transfusion to treat or prevent bleeding in patients with thrombocytopenia. In this preparation, platelets collected from a donor are maintained in a portion of the donor's own plasma, which provides the necessary environment for platelet viability and function. This specific preparation was utilized by the Etablissement Français du Sang (EFS) as a reference arm in the EFFIPAP clinical trial to compare the hemostatic efficacy of newer technologies, such as pathogen-reduced platelets and platelets stored in additive solutions, in patients with bone marrow aplasia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Platelet concentrates in autologous plasma.